← 產業報告目錄
PD-1 Inhibitor Drugs Market Size, Share & Trends Analysis Report By Drug Type (Pembrolizumab, Nivolumab, Cemiplimab, Dostarlimab, Others), Indication (Melanoma, Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Kidney Cancer, Head And Neck Cancers, Stomach Cancer, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And By Segment Forecasts 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-11頁數 180報告編號 INSIGHTACE-b9d191625c
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2024 valuation of USD 40.5 Billion, the global PD-1 Inhibitor Drugs Market is poised to expand to USD 150.6 Billion by 2034, demonstrating a CAGR of 14.4% during the 2025–2034 forecast window.
At its core, PD-1 Inhibitor Drugs pertains to cancer immunotherapies that inhibit the pd-1 receptor on t cells, hindering cancer cells from resisting immune recognition. Stakeholders across the healthcare landscape are risingly turning to these solutions to meet contemporary demands.
The market's upward path is supported by rising healthcare spending, technological evolution, and the rising focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold considerable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and rising investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PD-1 Inhibitor Market Snapshot
Chapter 4. Global PD-1 Inhibitor Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on PD-1 Inhibitor Market Industry Trends
4.10. Global PD-1 Inhibitor Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. PD-1 Inhibitor Market Segmentation 1: By Drug Type, Estimates & Trend Analysis
5.1. Market Share by Drug Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:
5.2.1. Pembrolizumab
5.2.2. Nivolumab
5.2.3. Cemiplimab
5.2.4. Dostarlimab
5.2.5. Others
Chapter 6. PD-1 Inhibitor Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Melanoma
6.2.2. Hodgkin Lymphoma
6.2.3. Non-Small Cell Lung Cancer
6.2.4. Kidney Cancer
6.2.5. Head And Neck Cancers
6.2.6. Stomach Cancer
6.2.7. Others
Chapter 7. PD-1 Inhibitor Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. PD-1 Inhibitor Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global PD-1 Inhibitor Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.2.3. North America PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.2.4. North America PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
8.3. Europe
8.3.1. Europe PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.3.3. Europe PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.3.4. Europe PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.4.3. Asia Pacific PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.4.4. Asia Pacific PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
8.5. Latin America
8.5.1. Latin America PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.5.3. Latin America PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.5.4. Latin America PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.6.3. Middle East & Africa PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.6.4. Middle East & Africa PD-1 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Akeso Biopharma Co., Ltd.
9.2.1.1. Business Overview
9.2.1.2. Key Drug Type/Drug Type Overview
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Alphamab Oncology
9.2.3. Amgen Inc.
9.2.4. AstraZeneca
9.2.5. BeiGene LTD.
9.2.6. Bristol-Myers Squibb Company
9.2.7. Eli Lilly and Company.
9.2.8. F. Hoffmann-La Roche AG
9.2.9. Gilead Sciences, Inc.
9.2.10. GSK plc.
9.2.11. Innovent
9.2.12. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
9.2.13. Merck & Co., Inc.
9.2.14. Eli Lilly and Company
9.2.15. Boehringer Ingelheim International GmbH.
9.2.16. Other prominent players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們